Bristol Myers - Merck's Thalassemia Candidate Under FDA Priority Review

The FDA has accepted for review Bristol Myers Squibb Co's BMY supplemental application seeking approval for Reblozyl (luspatercept-aamt) in adults with non-transfusion dependent (NTD) beta-thalassemia.

  • The FDA has set a Prescription Drug User Fee Act goal date of March 27, 2022.
  • In addition, the European Medicines Agency has validated the Type II variation for Reblozyl in NTD beta-thalassemia. 
  • Reblozyl is being co-developed and co-commercialized with Merck & Co Inc MRK following Merck's recent acquisition of Acceleron Pharma Inc.
  • These applications were based on safety and efficacy results from the pivotal Phase 2 BEYOND study evaluating Reblozyl plus best supportive care in patients with NTD beta-thalassemia.
  • See here Benzinga's Full FDA Calendar.
  • Price Action: BMY shares are up 1.77% at $56.39, while MRK stock is down 1.08% at $73.09 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralbeta thalassemiaBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!